Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Pre-Mkt 07-22 06:59:23 EDT

2.83

+0.04

+1.25%

盘前2.87

+0.04+1.41%

05:30 EDT

High2.86	Low2.78	Vol1.14M
Open2.84	D1 Closing2.80	Amplitude2.86%
Mkt Cap329.03M	Tradable Cap285.26M	Total Shares116.26M
T/O3.22M	T/O Rate1.13%	Tradable Shares100.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":2.83,"timestamp":1784664000000,"preClose":2.795,"halted":0,"volume":1143679,"hourTrading":{"tag":"盘前","latestPrice":2.87,"preClose":2.83,"latestTime":"05:30 EDT","volume":18331,"amount":51617.6084833,"timestamp":1784712622037,"change":0.04,"changeRate":0.014134,"amplitude":0.140212},"delay":0,"changeRate":0.012522361359570713,"floatShares":100797117,"shares":116263459,"eps":-1.089789,"marketStatus":"Pre-Mkt","change":0.035,"latestTime":"07-22 06:59:23 EDT","open":2.84,"high":2.86,"low":2.78,"amount":3222809.651828,"amplitude":0.028623,"askPrice":3.36,"askSize":100,"bidPrice":2.6,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.089789,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1784727000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":2.83,"preHourTrading":{"tag":"盘前","latestPrice":2.87,"preClose":2.83,"latestTime":"05:30 EDT","volume":18331,"amount":51617.6084833,"timestamp":1784712622037,"change":0.04,"changeRate":0.014134,"amplitude":0.140212},"postHourTrading":{"tag":"盘后","latestPrice":2.84,"preClose":2.83,"latestTime":"19:50 EDT","volume":5089,"amount":14463.1795,"timestamp":1784677827857,"change":0.01,"changeRate":0.003534,"amplitude":0.045936},"volumeRatio":0.4704309954643243,"impliedVol":0.807,"impliedVolPercentile":0.244},"requestUrl":"/m/hq/s/FATE","defaultTab":"news","newsList":[{"id":"2650971931","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2650971931","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650971931?lang=en_us&edition=fundamental","pubTime":"2026-07-10 03:23","pubTimestamp":1783625029,"startTime":"0","endTime":"0","summary":"Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF  down 0.4%.The iShares Biotechnology ETF  increased 0.3%.In corporate news, Fate Therapeutics  shares rose nearly 6% after the US Food and Drug Administration approved the company's investigational new drug application for FT839, a product candidate to treat autoimmune diseases.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","IBB","BK4139","FATE","LU0128526141.USD","LABU","LU0029874061.USD","XBI","XLV","HCSG","BK4588","BK4137","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650797509","title":"Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839","url":"https://stock-news.laohu8.com/highlight/detail?id=2650797509","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650797509?lang=en_us&edition=fundamental","pubTime":"2026-07-10 02:47","pubTimestamp":1783622867,"startTime":"0","endTime":"0","summary":"Fate Therapeutics  shares were up more than 7% in Thursday trading after the US Food and Drug Administration approved the company's investigational new drug application for FT839, a product candidate designed to treat autoimmune diseases.The company said that it now plans to advance FT839 into a trial designed to assess the product candidate across several autoimmune diseases, when given in combination with standard-of-care therapy and without conditioning chemotherapy.Fate said enrollment in the phase 1/2 trial is expected to start in H2.Price: 3.14, Change: +0.21, Percent Change: +7.17","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LABU","BK4588","FATE","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650196973","title":"Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2650196973","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650196973?lang=en_us&edition=fundamental","pubTime":"2026-07-09 23:25","pubTimestamp":1783610728,"startTime":"0","endTime":"0","summary":"In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Fate Therapeutics, with a price target of $7.00. Robert Bu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/fate-therapeutics-ft839-advancement-and-autoimmune-potential-underpin-buy-rating-12-month-7-price-target-reaffirmed-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/fate-therapeutics-ft839-advancement-and-autoimmune-potential-underpin-buy-rating-12-month-7-price-target-reaffirmed-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650924817","title":"Fate Therapeutics Wins FDA IND Clearance for Dual-target CAR-T Candidate FT839","url":"https://stock-news.laohu8.com/highlight/detail?id=2650924817","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650924817?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:33","pubTimestamp":1783600398,"startTime":"0","endTime":"0","summary":"Fate Therapeutics wins FDA IND clearance for dual-target CAR-T candidate FT839FDA cleared Fate Therapeutics’ IND for FT839, an off-the-shelf dual-target CAR T-cell therapy aimed at autoimmune disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDLFkPtm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU0314104364.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4585","IE00B3QW5Z07.USD","FATE","LU2210149790.SGD","BK4139","IE00BN0W2W23.USD","BK4588","IE00BGHQF748.EUR","NDAQ","LU2210150020.SGD","BK4112","IE00BN0W2T93.GBP","SG9999014039.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","SG9999014005.SGD","LU2095319765.USD","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650921035","title":"Fate Therapeutics - Enrollment in Phase 1/2 Study of FT839 Expected to Begin in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650921035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650921035?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:30","pubTimestamp":1783600201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nTUALWKYZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650492103","title":"Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2650492103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650492103?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:30","pubTimestamp":1783600201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nTUALWKYZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650084921","title":"Fate Therapeutics - FT839 Trial to Initially Target Rheumatoid Arthritis, Vasculitis, Myositis, Lupus, Systemic Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2650084921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650084921?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:30","pubTimestamp":1783600201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nTUALWKYZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649621967","title":"Fate Therapeutics - FT819 Also Being Evaluated in Sle; Phase 2 Trial Planned in Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2649621967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649621967?lang=en_us&edition=fundamental","pubTime":"2026-07-06 20:32","pubTimestamp":1783341120,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nFWN4380HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649621424","title":"Fate Therapeutics Reports Preliminary FT819 CAR-T Data Showing Skin Score Improvement in Systemic Sclerosis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2649621424","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649621424?lang=en_us&edition=fundamental","pubTime":"2026-07-06 20:31","pubTimestamp":1783341076,"startTime":"0","endTime":"0","summary":"Fate Therapeutics reports preliminary FT819 CAR-T data showing skin score improvement in systemic sclerosis patientsFate Therapeutics announced preliminary Phase 1 clinical data for FT819 in systemic ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL1N61Hc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","NDAQ","FATE","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4139","BK4588","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014021.USD","LU0314104364.USD","LU2210149790.SGD","BCDF","IE00B3QW5Z07.USD","BK4585","BK4112","SG9999014039.USD","IE00BN0W2T93.GBP","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648526846","title":"Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2648526846","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648526846?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:05","pubTimestamp":1782936300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, July  01, 2026  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/01/3320987/24675/en/Fate-Therapeutics-to-Participate-in-Upcoming-Third-Quarter-2026-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645890886","title":"H.C. Wainwright Reaffirms Their Buy Rating on Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645890886","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645890886?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:35","pubTimestamp":1782300949,"startTime":"0","endTime":"0","summary":"In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Fate Therapeutics, with a price target of $7.00. According...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-fate-therapeutics-fate-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-fate-therapeutics-fate-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645107522","title":"Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2645107522","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645107522?lang=en_us&edition=fundamental","pubTime":"2026-06-22 23:15","pubTimestamp":1782141313,"startTime":"0","endTime":"0","summary":"In a report released today, from Mizuho Securities maintained a Buy rating on Fate Therapeutics, with a price target of $8.00. Currently, the analy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/fate-therapeutics-fate-gets-a-buy-from-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/fate-therapeutics-fate-gets-a-buy-from-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","MFG","BK4207","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643789310","title":"Fate Therapeutics Shareholders Back Directors and Governance Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2643789310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643789310?lang=en_us&edition=fundamental","pubTime":"2026-06-16 05:12","pubTimestamp":1781557956,"startTime":"0","endTime":"0","summary":"An announcement from Fate Therapeutics ( ($FATE) ) is now available. At its annual meeting of stockholders held on June 12, 2026, Fate Therapeutics...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-shareholders-back-directors-and-governance-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-shareholders-back-directors-and-governance-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643078538","title":"Fate Therapeutics shareholders approve 7 million-share increase to equity incentive plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2643078538","media":"Reuters","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643078538?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:04","pubTimestamp":1781553848,"startTime":"0","endTime":"0","summary":"Fate Therapeutics held its annual shareholder meeting on June 12, 2026.Shareholders adopted a third amended and restated 2022 Stock Option and Incentive Plan, adding 7 million shares to the pool.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL5pvfBm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643209973","title":"BRIEF-Fate Therapeutics Appoints Laura Hamill To Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2643209973","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643209973?lang=en_us&edition=fundamental","pubTime":"2026-06-15 21:47","pubTimestamp":1781531235,"startTime":"0","endTime":"0","summary":"BRIEF-Fate Therapeutics Appoints Laura Hamill To Board Of DirectorsJune 15 (Reuters) - Fate Therapeutics Inc FATE.O:FATE THERAPEUTICS APPOINTS LAURA HAMILL TO BOARD OF DIRECTORSSource text: ID:nGNXbBYhvsFurther company coverage: FATE.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA1G2JY7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643205812","title":"Fate Therapeutics appoints former Gilead commercial chief Laura Hamill to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2643205812","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643205812?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:30","pubTimestamp":1781526642,"startTime":"0","endTime":"0","summary":"Fate Therapeutics appointed Laura Hamill to its board on June 15, 2026.Hamill previously served as EVP, Worldwide Commercial Operations at Gilead Sciences, overseeing about $22 billion in annual revenue.She spent nearly two decades at Amgen, including as SVP, U.S. Commercial Operations, leading a business unit representing roughly 80% of company revenue.Fate is positioning for later-stage development and an expected transition toward commercialization of its iPSC-derived cell therapy programs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL5dVbRv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU1061106388.HKD","GILD","IE00BKVL7J92.USD","BK4581","IE00BSNM7G36.USD","NDAQ","LU1839511570.USD","LU0109394709.USD","IE00BN0W2T93.GBP","IE00BJT1NW94.SGD","BK4534","IE00B7SZLL34.SGD","LU0234570918.USD","SG9999015945.SGD","SG9999014021.USD","BK4533","BK4599","LU1037948541.HKD","LU0320765992.SGD","LU0861579265.USD","LU0868494617.USD","AMGN","LU0965509010.AUD","BK4139","IE00B3QW5Z07.USD","LU0314104364.USD","LU2324357040.USD","FATE","LU1066053197.SGD","LU2242652126.USD","SG9999014039.USD","LU0965509101.SGD","LU2210150020.SGD","IE00B4R5TH58.HKD","SG9999015952.SGD","LU1934455194.USD","LU0823416689.USD","LU2112291526.USD","LU2242646821.SGD","SG9999014005.SGD","LU0122379950.USD","IE00B19Z3581.USD","BK4568","LU0058720904.USD","IE00BGHQF748.EUR","LU2468319806.SGD","LU1023059063.AUD","BK4578","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203047","title":"Press Release: Fate Therapeutics Appoints Laura Hamill to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203047","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203047?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:30","pubTimestamp":1781526600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, June 15, 2026  -- Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell -derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced the appointment of Laura Hamill to its Board of Directors. Ms. Hamill is a global senior executive with more than three decades of commercial and strategic management experience across the biopharmaceutical industry.Ms. Hamill most recently served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., where she was responsible for approximately $22 billion in annual revenue and an organization of 2,500 employees. In that role she led the transformation of Gilead's global commercial organization, advancing its structure, governance and capabilities, to return the business to revenue growth. Prior to Gilead, Ms. Hamill spent nearly two decades at Amgen, where she was repeated","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642628154","title":"Piper Sandler Remains a Buy on Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642628154","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642628154?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:18","pubTimestamp":1781003890,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Fate Therapeutics today and set a price target of $6.00. Tenthoff covers the Healt...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-fate-therapeutics-fate-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-fate-therapeutics-fate-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641485788","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2641485788","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641485788?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:30","pubTimestamp":1780914611,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fate Therapeutics (FATE), Atai Beckley N.V. (ATAI) a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-210?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-210?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","ATAI","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641548598","title":"Fate Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2641548598","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641548598?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:30","pubTimestamp":1780914600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FATE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 08, 2026 06:30 ET (10:30 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0535},{"period":"1month","weight":0.3541},{"period":"3month","weight":1.0657},{"period":"6month","weight":1.264},{"period":"1year","weight":1.4609},{"period":"ytd","weight":1.8801}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0021},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.1901},{"period":"ytd","weight":0.0973}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.049458},{"month":2,"riseRate":0.615385,"avgChangeRate":0.078089},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.020579},{"month":4,"riseRate":0.615385,"avgChangeRate":0.004138},{"month":5,"riseRate":0.461538,"avgChangeRate":0.079338},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.000833},{"month":7,"riseRate":0.461538,"avgChangeRate":0.05004},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.024603},{"month":9,"riseRate":0.416667,"avgChangeRate":0.00072},{"month":10,"riseRate":0.25,"avgChangeRate":-0.091603},{"month":11,"riseRate":0.538462,"avgChangeRate":0.090829},{"month":12,"riseRate":0.538462,"avgChangeRate":0.045045}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}